<html><head></head><body><h1>DiphenhydrAMINE (Systemic)</h1><ul class="ddc-anchor-links"><li>Pharmacology</li>
<li>Uses</li>
<li>Contraindications</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li>
<li>FAQ</li></ul><h2>Pronunciation</h2><p>(dye fen HYE dra meen)</p><h2>Index Terms</h2><ul><li>Benadryl</li><li>Diphenhydramine Citrate</li><li>Diphenhydramine HCl</li><li>Diphenhydramine Hydrochloride</li><li>Diphenhydramine Tannate</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p><p>Capsule, Oral, as hydrochloride: </p><p>Allergy Relief: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), butylparaben, edetate (edta) calcium disodium, fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), methylparaben, polysorbate 80, propylparaben]</p><p>Banophen: 25 mg, 50 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p><p>Benadryl Allergy: 25 mg [dye free]</p><p>Diphenhist: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p><p>Genahist: 25 mg</p><p>Geri-Dryl: 25 mg</p><p>GoodSense Allergy Relief: 25 mg [dye free]</p><p>GoodSense Sleep Aid: 50 mg [gluten free; contains brilliant blue fcf (fd&amp;c blue #1)]</p><p>Ormir: 50 mg [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p><p>Pharbedryl: 25 mg, 50 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p><p>Q-Dryl: 25 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), butylparaben, fd&amp;c red #40, methylparaben, propylparaben]</p><p>ZzzQuil: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p><p>Generic: 25 mg, 50 mg</p><p>Elixir, Oral, as hydrochloride: </p><p>Diphen: 12.5 mg/5 mL (118 mL) [contains alcohol, usp, fd&amp;c red #40; cinnamon-anise flavor]</p><p>Generic: 12.5 mg/5 mL (5 mL, 10 mL)</p><p>Liquid, Oral, as hydrochloride: </p><p>Allergy Childrens: 12.5 mg/5 mL (118 mL, 236 mL, 473 mL) [alcohol free, dye free; contains saccharin sodium, sodium benzoate, sorbitol]</p><p>Allergy Relief Childrens: 12.5 mg/5 mL (118 mL, 480 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate; cherry flavor]</p><p>Aurodryl Allergy Childrens: 12.5 mg/5 mL (118 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate; cherry flavor]</p><p>Banophen: 12.5 mg/5 mL (118 mL [DSC]) [alcohol free; cherry flavor]</p><p>Banophen: 12.5 mg/5 mL (473 mL [DSC]) [alcohol free, sugar free; cherry flavor]</p><p>Benadryl Allergy Childrens: 12.5 mg/5 mL (118 mL, 236 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p><p>Benadryl Allergy Childrens: 12.5 mg/5 mL (236 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate; cherry flavor]</p><p>Benadryl Allergy Childrens: 12.5 mg/5 mL (118 mL) [alcohol free, dye free, sugar free; contains saccharin sodium, sodium benzoate]</p><p>Di-Phen: 12.5 mg/5 mL (118 mL) [contains alcohol, usp, fd&amp;c red #40; cinnamon-anise flavor]</p><p>Diphenhist: 12.5 mg/5 mL (118 mL [DSC], 473 mL [DSC]) [alcohol free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate; fruit flavor]</p><p>Geri-Dryl: 12.5 mg/5 mL (473 mL) [alcohol free; contains fd&amp;c red #40, methylparaben, propylene glycol, propylparaben]</p><p>Geri-Dryl: 12.5 mg/5 mL (473 mL [DSC]) [alcohol free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate]</p><p>M-Dryl: 12.5 mg/5 mL (120 mL, 473 mL) [alcohol free; contains fd&amp;c red #40, propylene glycol, saccharin sodium, sodium benzoate; cherry flavor]</p><p>Naramin: 12.5 mg/5 mL (5 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate; cherry flavor]</p><p>PediaCare Childrens Allergy: 12.5 mg/5 mL (118 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p><p>Q-Dryl: 12.5 mg/5 mL (118 mL [DSC], 237 mL [DSC], 473 mL [DSC]) [alcohol free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate]</p><p>Scot-Tussin Allergy Relief: 12.5 mg/5 mL (118.3 mL [DSC], 240 mL [DSC], 480 mL [DSC], 3780 mL [DSC]) [alcohol free, dye free, saccharin free, sodium free, sorbitol free, sugar free]</p><p>Siladryl Allergy: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [alcohol free, sugar free; contains fd&amp;c red #40, methylparaben, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p><p>Total Allergy Medicine: 12.5 mg/5 mL (118 mL) [alcohol free]</p><p>ZzzQuil: 50 mg/30 mL (177 mL, 354 mL) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, propylene glycol, saccharin sodium, sodium benzoate; berry flavor]</p><p>ZzzQuil: 50 mg/30 mL (354 mL) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, propylene glycol, saccharin sodium, sodium benzoate; vanilla cherry flavor]</p><p>ZzzQuil: 50 mg/30 mL (177 mL, 354 mL) [alcohol free; contains brilliant blue fcf (fd&amp;c blue #1), propylene glycol, saccharin sodium, sodium benzoate; mango berry flavor]</p><p>Generic: 12.5 mg/5 mL (5 mL, 10 mL, 118 mL, 473 mL); 6.25 mg/mL (30 mL)</p><p>Solution, Injection, as hydrochloride: </p><p>Generic: 50 mg/mL (1 mL, 10 mL)</p><p>Solution, Injection, as hydrochloride [preservative free]: </p><p>Generic: 50 mg/mL (1 mL)</p><p>Strip, Oral, as hydrochloride: </p><p>Triaminic Cough/Runny Nose: 12.5 mg (16 ea [DSC]) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p><p>Syrup, Oral, as hydrochloride: </p><p>Silphen Cough: 12.5 mg/5 mL (118 mL [DSC], 237 mL [DSC], 473 mL [DSC]) [contains alcohol, usp, fd&amp;c red #40, menthol, methylparaben, propylene glycol, propylparaben; strawberry flavor]</p><p>Tablet, Oral, as hydrochloride: </p><p>Aler-Dryl: 50 mg</p><p>Anti-Hist Allergy: 25 mg</p><p>Banophen: 25 mg</p><p>Benadryl Allergy: 25 mg</p><p>Complete Allergy Medication: 25 mg [DSC]</p><p>Complete Allergy Relief: 25 mg</p><p>Diphen: 25 mg</p><p>Diphenhist: 25 mg [DSC]</p><p>Geri-Dryl: 25 mg</p><p>Nighttime Sleep Aid: 25 mg</p><p>Nytol: 25 mg</p><p>Nytol Maximum Strength: 50 mg</p><p>Simply Sleep: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p><p>Sleep Tabs: 25 mg [scored; contains fd&amp;c blue #1 aluminum lake]</p><p>Sominex: 25 mg [DSC] [contains fd&amp;c blue #1 aluminum lake]</p><p>Tetra-Formula Nighttime Sleep: 50 mg [contains fd&amp;c blue #1 aluminum lake]</p><p>Total Allergy: 25 mg</p><p>Generic: 25 mg</p><p>Tablet Chewable, Oral, as hydrochloride: </p><p>Benadryl Allergy Childrens: 12.5 mg [contains fd&amp;c blue #1 aluminum lake]</p><h2>Brand Names: U.S.</h2><ul><li>Aler-Dryl [OTC]</li><li>Allergy Childrens [OTC]</li><li>Allergy Relief Childrens [OTC]</li><li>Allergy Relief [OTC]</li><li>Anti-Hist Allergy [OTC]</li><li>Aurodryl Allergy Childrens [OTC]</li><li>Banophen [OTC]</li><li>Benadryl Allergy Childrens [OTC]</li><li>Benadryl Allergy [OTC]</li><li>Complete Allergy Medication [OTC] [DSC]</li><li>Complete Allergy Relief [OTC]</li><li>Di-Phen</li><li>Diphen</li><li>Diphen [OTC]</li><li>Diphenhist [OTC]</li><li>Genahist [OTC]</li><li>Geri-Dryl [OTC]</li><li>GoodSense Allergy Relief [OTC]</li><li>GoodSense Sleep Aid [OTC]</li><li>M-Dryl [OTC]</li><li>Naramin [OTC]</li><li>Nighttime Sleep Aid [OTC]</li><li>Nytol Maximum Strength [OTC]</li><li>Nytol [OTC]</li><li>Ormir [OTC]</li><li>PediaCare Childrens Allergy [OTC]</li><li>Pharbedryl [OTC]</li><li>Q-Dryl [OTC] [DSC]</li><li>Scot-Tussin Allergy Relief [OTC] [DSC]</li><li>Siladryl Allergy [OTC]</li><li>Silphen Cough [OTC] [DSC]</li><li>Simply Sleep [OTC]</li><li>Sleep Tabs [OTC]</li><li>Sominex [OTC] [DSC]</li><li>Tetra-Formula Nighttime Sleep [OTC]</li><li>Total Allergy Medicine [OTC]</li><li>Total Allergy [OTC]</li><li>Triaminic Cough/Runny Nose [OTC] [DSC]</li><li>ZzzQuil [OTC]</li></ul><h2>Pharmacologic Category</h2><ul><li>Ethanolamine Derivative</li><li>Histamine H<sub>1</sub> Antagonist</li><li>Histamine H<sub>1</sub> Antagonist, First Generation</li></ul><h2 class="ddc-anchor-offset" id="pharmacology">Pharmacology</h2><p>Competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; anticholinergic and sedative effects are also seen</p><h3>Distribution</h3><p>V<sub>d</sub>: Children: 22 L/kg (range: 15 to 28 L/kg); Adults: 17 L/kg (range: 13 to 20 L/kg); Elderly: 14 L/kg (range: 7 to 20 L/kg) (Blyden 1986; Simons 1990)</p><h3>Metabolism</h3><p>Extensively hepatic n-demethylation via CYP2D6; minor demethylation via CYP1A2, 2C9 and 2C19; smaller degrees in pulmonary and renal systems; significant first-pass effect (Akutsu 2007)</p><h3>Excretion</h3><p>Urine (as metabolites and unchanged drug) (Albert 1975; Maurer 1988)</p><h3>Time to Peak</h3><p>Serum: ~2 hours (Blyden 1986; Simons 1990)</p><h2>Duration of Action</h2><p>Histamine-induced wheal suppression: ≤10 hours (Simons 1990)</p><p>Histamine-induced flare suppression: ≤12 hours (Simons 1990)</p><h3>Half-Life Elimination</h3><p>Children: 5 hours (range: 4 to 7 hours); Adults: 9 hours (range: 7 to 12 hours); Elderly: 13.5 hours (range: 9 to 18 hours) (Blyden 1986; Simons 1990)</p><h3>Protein Binding</h3><p>98.5% (Vozeh 1988)</p><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p>Symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis; adjunct to epinephrine in the treatment of anaphylaxis; insomnia, occasional; prevention or treatment of motion sickness; antitussive; management of parkinsonian syndrome including drug-induced extrapyramidal symptoms (dystonic reactions) alone or in combination with centrally acting anticholinergic agents</p><p><b><i>Guideline recommendations: </i></b></p><p><i>Anaphylaxis:</i> Antihistamines are considered second-line treatment only after epinephrine administration in the adjunct management of anaphylaxis (AAAAI [Lieberman 2015]).</p><p><i>Insomnia:</i> American Academy of Sleep Medicine guidelines for the treatment of chronic insomnia suggest diphenhydramine not be used for sleep-onset or sleep-maintenance insomnia in adults due to the absence of evidence for clinically significant improvement (AASM [Sateia 2017]). The US Department of Veterans Affairs/Department of Defense guidelines for the chronic management of insomnia disorder and obstructive sleep apnea suggest against the use of diphenhydramine for chronic insomnia (VA/DoD 2019).</p><h2>Off Label Uses</h2><h3>Angioedema, allergic (acute)</h3><p>Clinical experience suggests the utility of diphenhydramine in the management of allergic angioedema <sup>[James 2017]</sup>, <sup>[Zuraw 2019]</sup>. Diphenhydramine should <b>not</b> be used as monotherapy for angioedema with anaphylaxis; use epinephrine if anaphylaxis symptoms are present.</p><h3>Infusion- or transfusion-related reactions</h3><p>Clinical experience suggests the utility of diphenhydramine for the prevention of infusion-related reactions and in the treatment of infusion- or transfusion-related reactions as an adjunct to other appropriate measures (eg, stopping the infusion, reducing the infusion rate). An optimal premedication regimen has not been identified; refer to institutional protocols <sup>[Castells 2019]</sup>. Diphenhydramine should <b>not</b> be used as initial or sole treatment of anaphylaxis; use epinephrine if anaphylaxis symptoms are present.</p><h3>Nausea and vomiting, pregnancy associated, severe or refractory</h3><p>Based on the Society of Obstetricians and Gynaecologists of Canada guideline on nausea and vomiting of pregnancy and the American College of Obstetricians and Gynecologists practice bulletin, use of diphenhydramine may be considered in the treatment of refractory nausea and vomiting when preferred agents do not provide initial symptom improvement <sup>[ACOG 2018]</sup>, <sup>[Arsenault 2002]</sup>, <sup>[Magee 2002]</sup>.</p><h3>Scombroid (histamine) poisoning</h3><p>Clinical experience suggests the utility of diphenhydramine in the treatment of scombroid (histamine) poisoning <sup>[Taylor 1989]</sup>.</p><h3>Urticaria</h3><p>Based on the European Academy of Allergology and Clinical Immunology/Global Asthma and Allergy European Network/European Dermatology Forum/World Allergy Organization guidelines for the management of urticaria, diphenhydramine may be considered in the treatment of acute and chronic urticaria <sup>[Zuberbier 2018]</sup>.</p><h3>Vertigo, acute treatment</h3><p>Clinical experience suggests the utility of diphenhydramine in the acute treatment of vertigo <sup>[Furman 2019]</sup>, <sup>[Zajonc 2006]</sup>.</p><p>Based on the American Academy of Otolaryngology–Head and Neck Surgery guidelines for the treatment of Ménière disease, diphenhydramine is effective and recommended in the management of acute vertigo attacks in patients with Ménière disease <sup>[Basura 2020]</sup>.</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>Hypersensitivity to diphenhydramine, other structurally related antihistamines, or any component of the formulation; neonates or premature infants; breast-feeding</p><p>Additional contraindications: Parenteral: Use as a local anesthetic</p><p>OTC labeling: When used for self-medication, do not use in children &lt;6 years, to make a child sleep, or with any other diphenhydramine-containing products (including topical products)</p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Note: </b>Dosing recommendations based on clinical experience and general dosing range in manufacturer's labeling unless otherwise noted. Although oral dosing up to 50 mg every 4 hours (maximum: 300 mg/day) and parenteral dosing up to 100 mg every 6 hours (maximum: 400 mg/day) are approved in some labels, adverse effects may be increased at these higher doses. In general, clinical experience dictates that the doses provided below are sufficient.</p><p><b>Allergic reactions:</b></p><p><b><i>Anaphylaxis (adjunct to epinephrine):</i> Note: </b>Administer epinephrine first when treating anaphylaxis. Do <b>not</b> use diphenhydramine for initial or sole treatment of anaphylaxis because H<sub>1</sub> antihistamines do <b>not</b> relieve upper or lower airway obstruction, hypotension, or shock.</p><p>IV: 25 to 50 mg given after epinephrine (AAAAI [Lieberman 2015]; Simons 2011).</p><p><b><i>Mild to moderate cutaneous reactions (eg, pruritus):</i> Note: </b>May combine with a topical or systemic glucocorticoid and/or H<sub>2</sub> antihistamine, depending on the severity and/or cause of the allergic reaction.</p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p><p>IM, IV: 10 to 50 mg per dose every 6 hours as needed.</p><p><b>Angioedema, allergic (acute) (alternative agent) (off-label use): Note:</b> Should not be used as monotherapy for angioedema with anaphylaxis; use epinephrine, prior to diphenhydramine, if anaphylaxis symptoms are present (James 2017; Zuraw 2019).</p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p><p>IM, IV: 10 to 50 mg per dose every 6 hours as needed.</p><p><b>Common cold symptoms (eg, rhinitis, rhinorrhea, sneezing) or upper airway cough syndrome:</b> <b>Note:</b> Used in combination with a decongestant; adverse effects of monotherapy likely outweigh benefits (Björnsdóttir 2007; De Sutter 2012; De Sutter 2015; Irwin 2006; Weinberger 2019).</p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed (in combination with a decongestant); doses at the higher end of the dosing range may not be tolerated.</p><p><b>Dystonic reactions, medication-induced: </b></p><p><b><i>Acute treatment:</i></b> <b>Note: </b>Parenteral administration is preferred for initial treatment of acute symptoms. Treatment should continue with oral administration for several days to prevent recurrence. Duration of anticholinergic therapy should be based on the severity of the dystonic reaction and pharmacokinetic properties (eg, half-life) of the causative agent (Holloman 1997; Lavonas 2019; Marder 2019; Tonda 1994).</p><p><i>Initial dose:</i> IM, IV: 25 to 50 mg once (Lavonas 2019).</p><p><i>Subsequent doses:</i> Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours, typically for 2 to 3 days (Lavonas 2019).</p><p><b><i>Prophylaxis:</i></b> <b>Note: </b>May be useful for preventing acute dystonic reactions when administering drugs with increased risk of causing such reactions (eg, haloperidol, metoclopramide) (Kreyenbuhl 2009).</p><p>IM, IV: 12.5 to 25 mg prior to administration of high-risk medication (Friedman 2009; Kelley 2012; Kreyenbuhl 2009; Marder 2019).</p><p><b>Infusion- or transfusion-related reactions (off-label use):</b></p><p><i><b>Premedication:</b></i> <b>Note: </b>Typically administered prior to the infusion of certain chemotherapy agents, biologics, or other drugs (eg, contrast media); may be given with a glucocorticoid, acetaminophen, and/or an H<sub>2</sub> antihistamine. An optimal premedication regimen has not been identified; refer to institutional protocols (Castells 2019). The routine use of premedication with diphenhydramine prior to blood transfusions to prevent febrile nonhemolytic or allergic transfusion reactions is not recommended or supported by data (Silvergleid 2019; Tobian 2007).</p><p>IV, Oral: 25 to 50 mg given ~30 to 60 minutes prior to infusion; use of the oral route may require earlier administration (eg, ~1 to 2 hours prior to infusion) to allow for adequate concentrations at the time of infusion or potential reaction.</p><p><b><i>Treatment: </i>Note:</b> Administer epinephrine first when treating anaphylaxis. Do <b>not</b> use diphenhydramine for initial or sole treatment of anaphylaxis because H<sub>1</sub> antihistamines do <b>not</b> relieve upper or lower airway obstruction, hypotension, or shock. Diphenhydramine should be used for symptomatic relief as an adjunct to other appropriate measures (eg, stopping the infusion, reducing the infusion rate).</p><p>IV, Oral: 25 to 50 mg; after 15 to 30 minutes, if symptoms persist, may repeat dose as needed. Do not exceed 100 mg within a 1-hour period (Silvergleid 2019). <b>Note: </b>With oral administration, onset of action is delayed.</p><p><b>Insomnia, occasional (alternative agent): Note:</b> Routine use is <b>not</b> recommended (AASM [Sateia 2017]).</p><p>Oral: 25 to 50 mg at bedtime for occasional use only.</p><p><b>Motion sickness: </b></p><p><b><i>Prophylaxis:</i></b> Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed. <b>Note: </b>Antihistamines may be administered 30 to 60 minutes before motion (Dramamine labeling 2019).</p><p><b><i>Treatment:</i></b></p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p><p>IM, IV: 10 to 50 mg per dose every 6 hours as needed.</p><p><b>Nausea and vomiting, p</b><b>regnancy associated, severe or refractory (alternative agent) (off-label use): Note:</b> May be considered as a component of combination therapy when symptoms persist following initial pharmacologic therapy (ACOG 2018).</p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed (ACOG 2018; Magee 2002).</p><p>IV: 10 to 50 mg every 6 hours as needed; some experts administer as often as every 4 hours as needed (Smith 2019).</p><p><b>Scombroid (histamine) poisoning (off-label use):</b> <b>Note: </b>For patients with uncomfortable symptoms (eg, flushing, burning, rash) but <b>without</b> respiratory distress or hypotension (Taylor 1989).</p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p><p>IM, IV: 10 to 50 mg per dose every 6 hours as needed.</p><p><b>Urticaria (alternative agent): Note: </b>Second-generation antihistamines are preferred (Zuberbier 2018); may consider use in young, healthy patients (eg, administered at bedtime with daytime use of a second-generation antihistamine) (Asero 2020; Khan 2020).</p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed. Alternatively, may administer 25 to 50 mg once daily at bedtime with daytime use of a second-generation antihistamine (Khan 2020).</p><p>IM, IV: 10 to 50 mg per dose every 6 hours as needed; some experts administer as often as every 4 hours as needed (Asero 2020).</p><p><b>Vertigo, acute treatment (off-label use): </b></p><p>Oral: 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed (Basura 2020; Furman 2019; Zajonc 2006).</p><p>IM, IV: 10 to 50 mg per dose every 6 hours as needed (Basura 2020; Furman 2019; Zajonc 2006).</p><p><b><i>Duration: </i></b>Discontinue as soon as severe symptoms resolve, usually after 1 to 2 days (Furman 2019).</p><p><b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p><h2>Dosing: Pediatric</h2><p><b>Note:</b> Oral solutions are available in 2 concentrations (ie, 12.5 mg/5 mL and 50 mg/30 mL [eg, ZzzQuil]); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as "mg;" the 50 mg/30 mL oral solution is only indicated for the occasional treatment of insomnia. Although 300 mg/<b>day</b> is listed in prescribing information, some experts suggest that 200 mg/<b>day</b> is adequate for most indications.</p><p><b>Allergic reaction (severe)/anaphylaxis (adjunct to epinephrine):</b> <b>Note:</b> Do not use as initial therapy; antihistamines are considered second- or third-line agents in the treatment of anaphylaxis (AAAAI/ACAAI [Lieberman 2015]; WAO [Simons 2011]; WAO [Simons 2015]).</p><p>Infants, Children, and Adolescents: IV, IM, Oral: 1 to 2 mg/kg/dose; may repeat every 6 hours; maximum dose: 50 mg/dose (AAAAI/ACAAI [Lieberman 2015]; Hegenbarth 2008; Liberman 2008; WHO [Simons 2011]).</p><p><b>Allergies; antihistamine; </b><b>hay fever:</b></p><p>Weight-based dosing: Infants, Children, and Adolescents: Oral: 5 mg/kg/day divided into 3 to 4 doses; maximum daily dose: 300 mg/<b>day</b>; age-related maximum daily doses may also be considered: &lt;6 years: 37.5 mg/<b>day </b>(Kliegman 2011); 6 to 11 years: 150 mg/<b>day</b>; ≥12 years: 300 mg/<b>day</b>.</p><p>Fixed dosing: Oral:</p><p>Children 2 to &lt;6 years: Limited data available: 6.25 mg every 4 to 6 hours (Kliegman 2011).</p><p>Children 6 to &lt;12 years: 12.5 to 25 mg every 4 to 6 hours.</p><p>Children ≥12 years and Adolescents: 25 to 50 mg every 4 to 6 hours.</p><p><b>Dystonic reactions/parkinsonism:</b> Infants, Children, and Adolescents:</p><p>Initial: IV, IM: 1 to 2 mg/kg/dose; maximum dose: 50 mg/dose; may repeat if necessary (Fuhrman 2015; Hegenbarth 2008).</p><p>Subsequent doses:</p><p>IV: 5 mg/kg/day in divided doses every 6 hours; <b>Note:</b> Usual adult dose: 25 to 50 mg/dose.</p><p>Oral: 5 mg/kg/day divided into 3 to 4 doses; <b>Note:</b> Usual adult dose: 25 to 50 mg/dose.</p><p><b>Insomnia; occasional:</b> <b>Note: </b>Evaluation of sleep hygiene and use of non-pharmacologic (ie, behavioral) treatment are preferred treatments; medications may be used as adjunct treatment (Owens 2005).</p><p>Children ≥2 years and Adolescents: Limited data available for &lt;12 years: Oral: 0.5 to 1 mg/kg administered 30 minutes before bedtime; usual dose: 12.5 to 50 mg/dose; maximum dose: 50 mg/dose (Felt 2014; Russo 1976).</p><p><b>Motion sickness:</b></p><p>Prophylaxis: <b>Note: </b>First dose should be administered 30 to 60 minutes before travel (CDC 2017).</p><p>Weight-based dosing:</p><p>Infants and Children &lt;2 years: Oral: 5 mg/kg/day divided into 3 to 4 doses; infants and toddlers are generally immune to motion sickness (CDC 2017).</p><p>Children ≥2 years: Oral: 0.5 to 1 mg/kg/dose every 6 hours; maximum dose: 25 mg/dose (CDC 2017).</p><p>Fixed dosing: Children and Adolescents: Oral: 12.5 to 25 mg 3 to 4 times daily.</p><p>Treatment: Infants, Children, and Adolescents:</p><p>IV, IM: 1.25 mg/kg/dose every 6 hours. <b>Note:</b> Usual adult dose: 10 to 50 mg/dose.</p><p>Oral: 5 mg/kg/day divided into 3 to 4 doses; usual dose: 12.5 to 25 mg/dose.</p><p><b>Urticaria/pruritus:</b> Infants, Children, and Adolescents: Oral: 5 mg/kg/day divided into 3 to 4 doses; usual dose: 12.5 to 25 mg/dose; maximum daily dose: 300 mg/<b>day</b>; <b>Note: </b>Guidelines do not recommend as first-line treatment for chronic urticaria (EAACI/GA<sup>2</sup>LEN/EDF/WAO [Zuberbier 2018]).</p><p><b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p><h2>Administration</h2><p>Oral: When used to prevent motion sickness, first dose should be given 30 minutes prior to exposure. When used for occasional insomnia, dose should be given 30 minutes before bedtime.</p><p>IM, IV: Injection solution is for IV or deep IM administration only. For IV administration, inject at a rate ≤25 mg/minute. Local necrosis may result with SubQ or intradermal use.</p><h2>Dietary Considerations</h2><p>Some products may contain sodium and/or phenylalanine.</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Injection: Store at room temperature of 20°C to 25°C (68°F to 77°F); protect from light and freezing. </p><p>Oral:  Store at room temperature.  Protect capsules and tablets from moisture. Protect oral solution from freezing and light.</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Monitor therapy</i></p><p>Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Monitor therapy</i></p><p>Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Monitor therapy</i></p><p>Amphetamines: May diminish the sedative effect of Antihistamines.<i> Monitor therapy</i></p><p>Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Monitor therapy</i></p><p>Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Consider therapy modification</i></p><p>Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. <i> Monitor therapy</i></p><p>Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Consider therapy modification</i></p><p>Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Monitor therapy</i></p><p>Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Consider therapy modification</i></p><p>Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Consider therapy modification</i></p><p>Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Monitor therapy</i></p><p>Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Avoid combination</i></p><p>CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Consider therapy modification</i></p><p>CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Monitor therapy</i></p><p>Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Avoid combination</i></p><p>Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Monitor therapy</i></p><p>Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Consider therapy modification</i></p><p>Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Avoid combination</i></p><p>Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Consider therapy modification</i></p><p>Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Monitor therapy</i></p><p>Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Monitor therapy</i></p><p>Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Avoid combination</i></p><p>Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Consider therapy modification</i></p><p>HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Monitor therapy</i></p><p>Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Monitor therapy</i></p><p>Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Consider therapy modification</i></p><p>Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Avoid combination</i></p><p>Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Avoid combination</i></p><p>Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Monitor therapy</i></p><p>Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Monitor therapy</i></p><p>Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Monitor therapy</i></p><p>Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Consider therapy modification</i></p><p>Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Avoid combination</i></p><p>Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Consider therapy modification</i></p><p>OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Consider therapy modification</i></p><p>Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Avoid combination</i></p><p>Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Consider therapy modification</i></p><p>Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Monitor therapy</i></p><p>Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Avoid combination</i></p><p>Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Avoid combination</i></p><p>Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Avoid combination</i></p><p>Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Monitor therapy</i></p><p>Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Avoid combination</i></p><p>Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Monitor therapy</i></p><p>Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Avoid combination</i></p><p>ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Monitor therapy</i></p><p>Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Monitor therapy</i></p><p>Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Monitor therapy</i></p><p>Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Consider therapy modification</i></p><p>Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Consider therapy modification</i></p><p>Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Avoid combination</i></p><p>Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Monitor therapy</i></p><p>Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Consider therapy modification</i></p><p>Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Avoid combination</i></p><p>Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Monitor therapy</i></p><p>Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Consider therapy modification</i></p><h2>Test Interactions</h2><p>May interfere with urine detection of methadone and phencyclidine (false-positives); may cause false-positive serum TCA screen; may suppress the wheal and flare reactions to skin test antigens</p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>Frequency not defined:</p><p>Cardiovascular: Chest tightness, extrasystoles, hypotension, palpitations, tachycardia</p><p>Central nervous system: Ataxia, chills, confusion, dizziness, drowsiness, euphoria, excitement, fatigue, headache, irritability, nervousness, neuritis, paradoxical excitation, paresthesia, restlessness, sedation, seizure, vertigo</p><p>Dermatologic: Diaphoresis, skin photosensitivity, skin rash, urticaria</p><p>Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes, epigastric distress, nausea, vomiting, xerostomia</p><p>Genitourinary: Difficulty in micturition, urinary frequency, urinary retention</p><p>Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, thrombocytopenia</p><p>Hypersensitivity: Anaphylactic shock</p><p>Neuromuscular &amp; skeletal: Tremor</p><p>Ophthalmic: Blurred vision, diplopia</p><p>Respiratory: Nasal congestion, pharyngeal edema, thickening of bronchial secretions, wheezing</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p><p><b><i>Disease-related concerns:</i></b></p><p>• Asthma: Use with caution in patients with a history of asthma.</p><p>• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p><p>• Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.</p><p>• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia, bladder neck obstruction, and/or GU obstruction.</p><p>• Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).</p><p>• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p><p><b><i>Special populations:</i></b></p><p>• Pediatric: Antihistamines may cause excitation in young children. Toxicity (overdose) in pediatric patients may result in hallucinations, convulsions, or death; neonates and young children are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates and premature infants.</p><p><b><i>Dosage form specific issues:</i></b></p><p>• Alcohol: Some oral liquid products may contain alcohol.</p><p>• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p><p>• Oral liquid: Oral solutions are available in two concentrations (ie, 12.5 mg/5 mL and 50 mg/30 mL [eg, ZzzQuil]); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as "mg"; the 50 mg/30 mL oral solution is indicated for the occasional treatment of insomnia.</p><p>• Parenteral: Subcutaneous or intradermal use has been associated with tissue necrosis; administer IV or IM only.</p><p>• Phenylalanine: Some products may contain phenylalanine.</p><p>• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer’s labeling.</p><p>• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar, 2007).</p><p>• Soy protein: Some preparations contain soy protein; avoid use in patients with soy protein or peanut allergies.</p><p><b><i>Other warnings/precautions:</i></b></p><p>• Self-medication (OTC use): Do not use with other products containing diphenhydramine, even ones used on the skin. Oral products are not for OTC use in children &lt;6 years of age.</p><h2>Monitoring Parameters</h2><p>Relief of symptoms, mental alertness</p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Risk Factor
B

Pregnancy Considerations</h2><p>Diphenhydramine crosses the placenta (Miller 2000; Parkin 1974).</p><p>Diphenhydramine may be used for the treatment of allergic conditions in pregnant women when a first-generation antihistamine is indicated (Babalola 2013; Murase 2014). Diphenhydramine may be used as adjunctive therapy in the management of nausea and vomiting of pregnancy when the preferred agents do not provide initial symptom improvement (ACOG 189 2018).</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to relieve coughing.</p><p>• It is used to ease allergy signs.</p><p>• It is used to help motion sickness.</p><p>• It is used to treat signs like Parkinson's disease caused by other health problems.</p><p>• It is used to treat sleep problems.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Fatigue</p><p>• Thickening of mucus</p><p>• Anxiety</p><p>• Vomiting</p><p>• Nausea</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Severe dizziness</p><p>• Passing out</p><p>• Decreased alertness</p><p>• Change in balance</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How much Benadryl can I take? What is too much?</li>
<li>Diphenhydramine Hydrochloride vs Citrate: What's the difference?</li>
</ul><h2>More about diphenhydramine</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>359 Reviews</li>
<li>Drug class: anticholinergic antiemetics</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Diphenhydramine &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Diphenhydramine Capsules &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Diphenhydramine Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Diphenhydramine Oral Solution &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Allergic Reactions</li>
<li>Allergic Rhinitis</li>
<li>Cold Symptoms</li>
<li>Cough</li>
<li data-more-config-id="list-data-resources-conditions">... +7 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>